Pricing Log in Create free account

Larimar Therapeutics, Inc. (LRMR) vs Lyell Immunopharma, Inc. (LYEL)

Larimar Therapeutics, Inc. and Lyell Immunopharma, Inc. are both Biotechnology companies. Larimar Therapeutics, Inc. and Lyell Immunopharma, Inc. are of similar size ($206.7M and $200.7M). Larimar Therapeutics, Inc. has the higher net margin (0.00% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 13 metrics below, Larimar Therapeutics, Inc. leads on 7 and Lyell Immunopharma, Inc. on 6.

Valuation

Metric LRMR LYEL Biotechnology median
P/E n/m n/m 8.50
P/S n/m 7,009.20 9.71
P/B 1.62 0.81 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.06 0.64
EV/Sales n/m (550.13) 9.21
Earnings yield (97.99%) (158.40%) (33.15%)
Free cash flow yield (75.51%) (92.40%) (25.50%)

Profitability

Metric LRMR LYEL Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (949,981.48%) 0.00%
Net margin 0.00% (920,285.19%) 0.00%
Free cash flow margin 0.00% (647,681.48%) 0.00%
Return on equity (138.41%) (93.28%) (56.36%)
Return on assets (108.53%) (71.34%) (48.04%)
Return on invested capital 0.00% (539.53%) 0.00%

Growth

Metric LRMR LYEL Biotechnology median
Revenue growth (TTM) — (55.00%) 6.02%
EPS growth (last fiscal year) (71.97%) 38.70% 30.26%
Revenue growth, 5-year CAGR — (65.85%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LRMR LYEL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.70 5.36 4.72
Net debt to EBITDA 0.79 0.94 0.96

Dividend

Metric LRMR LYEL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LRMR LYEL Biotechnology median
Market cap 206.73m 200.70m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack